The principal mission of the Duke Center for AIDS Research (CFAR) is to promote the collaboration and coordination of AIDS-related research by supporting the scientific needs of the basic and clinical HIV/AIDS research community at Duke. In this competitive renewal application, the new Duke CFAR seeks to use its newly established leadership role within the Medical Center to build upon the many important accomplishments of its first 4 years in existence and, in doing so, to further expand the overall infrastructure and programmatic support that will continue to provide cost effective state of the art essential services while also serving as a catalyst for future HIV/AIDS collaborative research initiatives at Duke. The highly successful Small Grant support mechanism as well as the active recruitment of 5 new key HIV/AIDS investigators to Duke both form a solid basis in moving forward into the next funding cycle. Through a highly effective Strategic Planning process, the Duke CFAR leadership, in consultation with the Duke CFAR External Advisory Committee has identified 4 priority areas for development and support over the next 5 years, that comprise the Specific Aims for this proposal and include 1) creation of an AIDS-associated malignancies basic and clinical research program at Duke in collaboration with the Duke Comprehensive Cancer Institute (DCCI), 2) development and support of a comprehensive clinical database and linked specimen repository, 3) programmatic focus on HIV pathogenesis and elimination of viral reservoirs through targeted RFAs and faculty recruitment support, and 4) full engagement of the human genomics leadership on campus through integration with the Duke CFAR. The joint CFAR-DCCI initiative for Aim 1 is further substantiated by philanthropic matching funds made available by the DCCI Director. During the initial year of new funding, the Duke CFAR service Cores will begin operating as 'partial'shared resources supported by discounted service fees and reduced CFAR investment, thus freeing funds for use in further expansion of the CFAR Cores and services as emerging needs and opportunities arise. In addition to its overall infrastructure support, the new Duke CFAR is now firmly entrenched in a highly-recognized leadership position at Duke and occupies an all important 'seat at the table'in the critical decision-making processes within the Medical Center. The CFAR leadership looks forward to providing enhanced services and support to the Duke HIV/AIDS research community in conjunction with the next 5 years of NIH funding.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI064518-07
Application #
8105503
Study Section
Special Emphasis Panel (ZAI1-JBS-A (J1))
Program Officer
Namkung, Ann S
Project Start
2005-07-15
Project End
2015-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
7
Fiscal Year
2011
Total Cost
$2,127,945
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Ramadhani, Habib O; Muiruri, Charles; Maro, Venance P et al. (2017) Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. AIDS Behav :
Han, Qifeng; Williams, Wilton B; Saunders, Kevin O et al. (2017) HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. J Virol 91:
Margolis, David M; Koup, Richard A; Ferrari, Guido (2017) HIV antibodies for treatment of HIV infection. Immunol Rev 275:313-323
Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221
Wang, Kening; Tomaras, Georgia D; Jegaskanda, Sinthujan et al. (2017) Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice J Virol 91:
Price, Alexander M; Dai, Joanne; Bazot, Quentin et al. (2017) Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. Elife 6:
Martinez, David R; Vandergrift, Nathan; Douglas, Ayooluwa O et al. (2017) Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. J Virol 91:
Marks, Florian; von Kalckreuth, Vera; Aaby, Peter et al. (2017) Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 5:e310-e323
Towe, Sheri L; Patel, Puja; Meade, Christina S (2017) The Acceptability and Potential Utility of Cognitive Training to Improve Working Memory in Persons Living With HIV: A Preliminary Randomized Trial. J Assoc Nurses AIDS Care 28:633-643
Kelly, Matthew S; Surette, Michael G; Smieja, Marek et al. (2017) The Nasopharyngeal Microbiota of Children With Respiratory Infections in Botswana. Pediatr Infect Dis J 36:e211-e218

Showing the most recent 10 out of 468 publications